Cepheid's Xpert BCR-ABL Ultra is a quantitative test for BCR-ABL major breakpoint (p210) transcripts that provides highly sensitive and on-demand molecular results.
New Ways. New Innovations. New Paths Towards Disease Management.
Cancer is Hard. Testing for it Shouldn’t Be.
Cepheid’s innovative oncology program offers a growing menu of molecular diagnostic tests that currently focus on cancers of the breast, bladder, and blood. Harnessing the power of quantitative PCR technology and the world’s most popular molecular diagnostics platform1, Cepheid oncology products provide on-site, on-demand, standardized, and reliable results.
With Cepheid’s proven “lab in a cartridge,” our tests give patients and their doctors peace of mind when it matters most. The pioneering mindset of our oncology team is bolstered by Cepheid’s strong molecular biology capabilities, extensive global infrastructure, and an unwavering commitment to scientific rigor.
Offer your patients with hematuria a non-invasive, urine-based test with a high NPV and sensitivity to increase the probability of detecting high-grade tumors.
Monitor bladder cancer patients using a non-invasive, molecular test with high NPV to increase the probability of detecting high grade tumors.
Discover a Better Path with Xpert BCR-ABL Ultra2
The high sensitivity of the Cepheid BCR-ABL test, Xpert BCR-ABL Ultra*, allows for monitoring of disease even at low levels, thereby providing an essential aid for clinicians to manage their patients with CML, using IS-standardized molecular testing.
Xpert BCR-ABL Ultra Resources:
Xpert® Bladder Cancer Detection3 & Xpert® Bladder Cancer Monitor3
Xpert Bladder Cancer Detection and Xpert Bladder Cancer Monitor* are two easy to use, non-invasive bladder cancer tests. Xpert Bladder Cancer Detection* is intended to detect the presence of bladder cancer in patients with hematuria. Xpert Bladder Cancer Monitor* is indicated as an aid to standard clinical evaluation in monitoring for bladder cancer recurrence in patients previously diagnosed with bladder cancer. Both tests measure five bladder cancer-specific biomarkers and require only a urine sample from
Visit the Xpert Bladder Cancer Detection Product Page
Xpert Bladder Cancer Detection & Monitor Resources:
Xpert Breast Cancer STRAT4
Xpert Breast Cancer STRAT4* is an mRNA-based test that standardizes and simplifies the assessment of ESR1, PGR, ERBB2, and MKi-67 breast cancer biomarkers. In less than 2 hours, the test provides objective and reproducible results that are well-correlated with central lab IHC/ISH methods. Clear and accurate results empower pathologists and oncologists.
Xpert Breast Cancer STRAT4* Resources:
Cepheid and Max Foundation collaboration impacts CML patients around the globe
Our BCR-ABL test is playing a pivotal role in Cepheid’s vision of making molecular testing accessible to patients everywhere. In 2012, Cepheid partnered with The Max Foundation, an organization that channels humanitarian donations of life-saving oncology products to underserved populations in countries where those products are not locally available.
Through this collaboration of shared values, Cepheid offers compassion pricing of its GeneXpert IV instruments and Xpert BCR-ABL test for CML patients in specified low- and middle-income countries. Cepheid is also a proud sponsor of the Max Foundation initiative, My PCR, a patient driven program with the mission of educating all CML patients about the importance of monitoring their treatment with PCR testing.
Journey Inside the Cepheid GeneXpert® Cartridge - 3D Animation
The cornerstone of the GeneXpert testing process is Cepheid's patented, self-contained, single use cartridge. Sample extraction, amplification and detection are all carried out within this self-contained "laboratory in a cartridge".
Meet our Game-Changing Platform
With over 20,000 installed systems worldwide, the GeneXpert System is the molecular testing platform of choice for most laboratory specialists. See how it’s helping clinicians everywhere make a more positive impact.
1. Based on July 2019 market research conducted by Kalorama Information with sample respondents in select countries.
2. CE IVD and US-IVD. In Vitro Diagnostic Medical Device. Not available in all counties.
3. CE IVD. In Vitro Diagnostic Medical Device. Not available in all counties. Not available in the United States.